Hyperfine (HYPR) EBT Growth (1y) (2022 - 2026)
Hyperfine (HYPR) EBT Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -29.12% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 53.94% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 45.44% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 12.65% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 29.89% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 31.69% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 13.05% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 71.38% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 17.94% |
| 10 | Hyperfine | 90.12 Mn | 45.35 Mn | 1.98 Mn | -0.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.79% |
| Mar 31, 2026 | 8.44% |
| Dec 31, 2025 | 43.10% |
| Sep 30, 2025 | -6.71% |
| Jun 30, 2025 | 9.17% |
| Mar 31, 2025 | 4.37% |
| Dec 31, 2024 | 2.75% |
| Sep 30, 2024 | 4.01% |
| Jun 30, 2024 | 4.52% |
| Mar 31, 2024 | 19.01% |
| Dec 31, 2023 | 18.19% |
| Sep 30, 2023 | 18.33% |
| Jun 30, 2023 | 54.07% |
| Mar 31, 2023 | 48.85% |
| Dec 31, 2022 | 49.94% |
| Sep 30, 2022 | 19.65% |
| Jun 30, 2022 | -58.84% |
| Mar 31, 2022 | -205.04% |